Hydroxychloroquine Treatment for Pediatric SLE Patients

Introduction to Hydroxychloroquine Treatment

The American College of Rheumatology recommends hydroxychloroquine (HCQ) be continued indefinitely (lifelong) in pediatric patients with Systemic Lupus Erythematosus (SLE) due to its beneficial effects on reducing renal flares, limiting organ damage, and improving long-term outcomes 1, 2

Hydroxychloroquine (HCQ) is recommended for all patients with SLE, including pediatric patients, as a cornerstone therapy that should be maintained indefinitely due to its multiple beneficial effects 2, 3
Epidemiological studies demonstrate that HCQ use is associated with higher rates of renal response, fewer renal flares, and reduced accrual of renal damage, supporting its long-term use 1

The recommended dose should not exceed 5 mg/kg real body weight per day to minimize risk of retinal toxicity while maintaining efficacy 2, 4
For pediatric patients, the dosing principles are the same as for adults, with no evidence suggesting that management should differ between children and adults 5

Annual ophthalmological screening should begin after 5 years of continuous treatment or sooner if there are risk factors for retinal damage 1
Regular monitoring should include body weight, blood pressure, serum creatinine, estimated GFR 1
Regular monitoring should also include serum albumin, proteinuria, urinary sediment 1
Regular monitoring should also include serum C3/C4, serum anti-dsDNA antibody levels, and complete blood cell count 1
Visits should be scheduled every 2-4 weeks for the first 2-4 months after diagnosis or flare, then every 3-6 months for lifelong monitoring 3

The risk of retinal toxicity increases with duration of treatment, with prevalence exceeding 10% after 20 years of continuous use 2
Major risk factors for retinopathy include duration of treatment, dose, chronic kidney disease, and pre-existing retinal or macular disease 2

Never discontinue HCQ abruptly as this may trigger disease flares 2
Patients in long-standing remission may have their dose lowered, although no studies have formally addressed this strategy in pediatric populations 2
Dose adjustments may be necessary in patients with GFR <30 ml/min 1